{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:07:33Z","timestamp":1787501253003,"version":"build-2736575974"},"reference-count":18,"publisher":"Galenos Yayinevi","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjo"],"published-print":{"date-parts":[[2022,4,1]]},"DOI":"10.4274\/tjo.galenos.2022.96461","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T07:35:19Z","timestamp":1651131319000},"page":"142-146","source":"Crossref","is-referenced-by-count":4,"title":["Half-fluence Photodynamic Therapy for Central Serous Chorioretinopathy in a Patient Receiving Corticosteroids for Beh\u00e7et\u2019s Uveitis"],"prefix":"10.4274","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5585-253X","authenticated-orcid":false,"given":"H\u00fcseyin Baran","family":"\u00d6zdemir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1171-0572","authenticated-orcid":false,"given":"Nazg\u00fcl","family":"Zhoroeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5714-7172","authenticated-orcid":false,"given":"P\u0131nar","family":"\u00c7akar \u00d6zdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-494X","authenticated-orcid":false,"given":"\u015eeng\u00fcl","family":"\u00d6zdek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","article-title":"Central serous chorioretinopathy: update on pathophysiology and treatment","volume":"58","author":"Nicholson","year":"2013","unstructured":"1. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58:103-126.","journal-title":"Surv Ophthalmol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3109\/09273948.2011.650776","article-title":"Central serous chorioretinopathy, corticosteroids, and uveitis","volume":"20","author":"Khairallah","year":"2012","unstructured":"2. Khairallah M, Kahloun R, Tugal-Tutkun I. Central serous chorioretinopathy, corticosteroids, and uveitis. Ocul Immunol Inflamm. 2012;20:76-85.","journal-title":"Ocul Immunol Inflamm"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/1752-1947-5-208","article-title":"Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report","volume":"5","author":"WW","year":"2011","unstructured":"3. Ng WW, Wu ZH, Lai TY. Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report. J Med Case Rep. 2011;5:208.","journal-title":"J Med Case Rep"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4274\/tjo.galenos.2018.83479","article-title":"Central Serous Chorioretinopathy: A Complication Associated with Beh\u00e7et's Disease Treatment","volume":"49","author":"Do\u011fanay","year":"2019","unstructured":"4. Do\u011fanay N, Bal\u0131ko\u011flu Y\u0131lmaz M, Orduy\u0131lmaz B, Ayd\u0131n E, Saat\u00e7i AO. Central Serous Chorioretinopathy: A Complication Associated with Beh\u00e7et's Disease Treatment. Turk J Ophthalmol. 2019;49:40-43.","journal-title":"Turk J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1080\/09273948.2019.1603312","article-title":"Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy","volume":"28","author":"Takayama","year":"2020","unstructured":"5. Takayama K, Obata H, Takeuchi M. Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy. Ocul Immunol Inflamm. 2020;28:509-512.","journal-title":"Ocul Immunol Inflamm"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/archopht.122.6.926","article-title":"Central serous chorioretinopathy associated with periocular corticosteroid injection treatment for HLA-B27-associated iritis","volume":"122","author":"Baumal","year":"2004","unstructured":"6. Baumal CR, Martidis A, Truong SN. Central serous chorioretinopathy associated with periocular corticosteroid injection treatment for HLA-B27-associated iritis. Arch Ophthalmol (Chicago, Ill : 1960). 2004;122:926-928.","journal-title":"Arch Ophthalmol (Chicago Ill"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/S0161-6420(02)01117-X","article-title":"Corticosteroids and central serous chorioretinopathy","volume":"109","author":"Carvalho-Recchia","year":"2002","unstructured":"7. Carvalho-Recchia CA, Yannuzzi LA, Negr\u00e3o S, Spaide RF, Freund KB, Rodriguez-Coleman H, Lenharo M, Iida T. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002;109:1834-1837.","journal-title":"Ophthalmology"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Sahoo NK, Singh SR, Chhablani J. Chapter 15 - CSCR Masquerades. In: Chhablani J, editor. Central Serous Chorioretinopathy: Academic Press; 2019. p. 193-211.","DOI":"10.1016\/B978-0-12-816800-4.00014-0"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000455267","article-title":"Central Serous Chorioretinopathy","volume":"58","author":"Daruich","year":"2017","unstructured":"9. Daruich A, Matet A, Behar-Cohen F. Central Serous Chorioretinopathy. Developments in ophthalmology. 2017;58:27-38.","journal-title":"Developments in ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.ophtha.2004.03.025","article-title":"Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy","volume":"111","author":"Sharma","year":"2004","unstructured":"10. Sharma T, Shah N, Rao M, Gopal L, Shanmugam MP, Gopalakrishnan M, Bhende P, Bhende M, Shetty NS, Baluswamy S. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology. 2004;111:1708-1714.","journal-title":"Ophthalmology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10067-018-4228-6","article-title":"Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients","volume":"38","author":"Fabiani","year":"2019","unstructured":"11. Fabiani C, Vitale A, Rigante D, Emmi G, Bitossi A, Lopalco G, Sota J, Guerriero S, Orlando I, Gentileschi S, Iannone F, Frediani B, Galeazzi M, Vannozzi L, Tosi GM, Cantarini L. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019;38:407-415.","journal-title":"Clin Rheumatol"},{"key":"ref11","unstructured":"12. \u00d6zdemir H, Arf Kara\u00e7orlu S, \u015eent\u00fcrk F, Kara\u00e7orlu M. Indocyanine Green Angiography-guided Photodynamic Therapy for Treatment of Chronic Central Serous Chorioretinopathy. Turk J Ophthalmol. 2008;38:499-503."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/ph13110349","article-title":"Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy","volume":"13","author":"Iacono","year":"2020","unstructured":"13. Iacono P, Da Pozzo S, Varano M, Parravano M. Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy. Pharmaceuticals (Basel). 2020;13:349.","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"102081","DOI":"10.1016\/j.pdpdt.2020.102081","article-title":"Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy","volume":"33","author":"Altinel","year":"2021","unstructured":"14. Altinel MG, Kanra AY, Totuk OMG, Ardagil A, Kabadayi K. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy. Photodiagnosis and photodynamic therapy. 2021;33:102081.","journal-title":"Photodiagnosis and photodynamic therapy"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00417-014-2926-6","article-title":"Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy","volume":"253","author":"Kim","year":"2015","unstructured":"15. Kim YK, Ryoo NK, Woo SJ, Park KH. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253:2063-2073.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1097\/IAE.0000000000000621","article-title":"Comparison Of Halving The Irradiation Time Or The Verteporfin Dose In Photodynamic Therapy For Chronic Central Serous Chorioretinopathy","volume":"35","author":"Shiode","year":"2015","unstructured":"16. Shiode Y, Morizane Y, Kimura S, Hosokawa M, Kawata T, Doi S, Hosogi M, Fujiwara A, Shiraga F. Comparison Of Halving The Irradiation Time Or The Verteporfin Dose In Photodynamic Therapy For Chronic Central Serous Chorioretinopathy. Retina. 2015;35:2498-2504.","journal-title":"Retina"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ajo.2014.01.022","article-title":"Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy","volume":"157","author":"Nicol\u00f3","year":"2014","unstructured":"17. Nicol\u00f3 M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2014;157:1033-1037.","journal-title":"Am J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/IAE.0000000000001138","article-title":"Comparison Of Photodynamic Therapy Using Half-Dose Of Verteporfin Or Half-Fluence Of Laser Light For The Treatment Of Chronic Central Serous Chorioretinopathy","volume":"37","author":"Cheng","year":"2017","unstructured":"18. Cheng CK, Chang CK, Peng CH. Comparison Of Photodynamic Therapy Using Half-Dose Of Verteporfin Or Half-Fluence Of Laser Light For The Treatment Of Chronic Central Serous Chorioretinopathy. Retina. 2017;37:325-333.","journal-title":"Retina"}],"container-title":["Turkish Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T09:02:08Z","timestamp":1721984528000},"score":1,"resource":{"primary":{"URL":"https:\/\/oftalmoloji.org\/articles\/doi\/tjo.galenos.2022.96461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4,1]]},"published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.4274\/tjo.galenos.2022.96461","relation":{},"ISSN":["1300-0659","2147-2661"],"issn-type":[{"value":"1300-0659","type":"print"},{"value":"2147-2661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}